Drug Profile
SAR 264565
Alternative Names: SAR264565Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Sanofi Aventis Deutschland GmbH
- Class Antiplatelets; Fab fragments; Glycoproteins
- Mechanism of Action Platelet membrane glycoprotein VI inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Thrombosis